Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
PSA Flare After First Lu-177 PSMA Injection Explained
A rising PSA after your first Lu-177 PSMA injection may be a temporary flare, not treatment failure. Learn what causes it, how your oncology team distinguishes it from true disease progression, and when to call your doctor without delay.
PRRT Second Opinion: What Really Determines Eligibility
A second opinion on PRRT eligibility can confirm whether lutetium Lu-177 dotatate is the right next step for your GEP-NET, or reveal that a different path fits better. Here is what to send, what gets evaluated, and when it changes the plan.
Continuing ADT During Lu-177 PSMA Therapy: What the Evidence Shows
Lutetium Lu-177 vipivotide tetraxetan is always given alongside maintained androgen deprivation therapy. Here is what the VISION trial evidence shows about combining both treatments, why the biology supports it, and what to expect.
Lu-177 PSMA for Frail mCRPC Patients Who Cannot Take Chemo
If chemotherapy carries too much risk for your body, Lu-177 PSMA therapy may still be a realistic option for mCRPC. Learn who qualifies under the expanded eligibility pathway and what the evidence shows for older and frailer patients.
Will Your Insurance Pay for Lu-177 PSMA Therapy
Insurance can cover Pluvicto for eligible mCRPC patients, but prior authorization is almost always required and denials are common. Here is how to build a strong appeal, what Medicare covers, and what financial assistance programs exist if coverage falls short.
What Your NET Pathology Grade Means for PRRT Eligibility
Your NET pathology report contains the key numbers - Ki-67 and tumor grade - that shape whether lutetium Lu-177 dotatate (PRRT) is an option for you. This guide explains what each result means, where the eligibility lines are drawn, and what to ask your oncologist next.
GEP-NET Types and When Lu-177 DOTATATE Is the Next Step
GEP-NETs are rare cancers of the gut and pancreas that often go undiagnosed for years. Learn what types exist, how tumor grade and somatostatin receptor expression shape your options, and when Lu-177 DOTATATE PRRT may be the right next step.
Lu-177 PSMA Pain Flare: What Every Patient Should Know
A pain flare - a temporary worsening of bone pain in the first week after an infusion - is a recognized side effect of Lu-177 PSMA therapy for mCRPC. Learn why it happens, how long it typically lasts, and how your care team will help you manage it.
How to Travel Safely Between Lu-177 PSMA Cycles
Most international patients can fly home between Lu-177 PSMA cycles - but timing, paperwork, and blood test coordination all matter. This guide covers what you need to know before you book your return flight.
How Ga-68 DOTATATE PET Determines Your PRRT Eligibility
The Ga-68 DOTATATE PET scan maps somatostatin receptors across your body and shows whether your neuroendocrine tumor cells carry enough of those receptors to make lutetium Lu 177 dotatate therapy (PRRT) a real option. This article explains how the scan works, how results are graded, and what your score means for treatment eligibility.
Erectile Dysfunction During Lu-177 PSMA Therapy
Erectile dysfunction is common in men receiving Lu-177 PSMA therapy for mCRPC - but the radioligand is rarely the direct cause. Understanding what drives ED during this treatment, and what options exist, can make a real difference to quality of life.
Lu-177 PSMA When Multiple Hormone Therapies Have Failed
If you have already tried abiraterone, enzalutamide, or apalutamide for mCRPC, the number of hormone therapies you have taken does not close the door on Lu-177 PSMA. What matters most is whether your tumors are still PSMA-positive on a PET scan.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.